Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2021-08-05 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Halfjaarverslag 2021.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 Halfjaarverslag' (2021 Half-Year Report) and contains comprehensive financial statements, management discussion and analysis, and an auditor's review report for the first six months of 2021. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-08-05 Dutch
6-K Filing
Regulatory Filings
2021-08-05 English
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
Earnings Release Classification · 95% confidence The document is a press release dated July 14, 2021, reporting 'topline results' from three clinical studies (Phase 1b and Phase 2a) for a drug candidate (GLPG3970) related to inflammatory diseases. It details safety, tolerability, and early efficacy signals (PASI score improvement, Mayo Score changes, DAS28 changes). This content structure—announcing specific, period-based clinical trial results for a drug candidate—is characteristic of an Earnings Release (ER) or a general press release announcing key operational/clinical milestones. Since it focuses purely on the immediate release of period-specific clinical trial results (topline data) rather than a comprehensive annual or quarterly financial report (10-K or IR), the most fitting category is 'Earnings Release' (ER), as these announcements often accompany or precede formal financial reporting periods to update investors on key operational progress. It is not a full financial report (10-K/IR), a transcript (CT), or a formal regulatory filing like a proxy statement (DEF 14A). It is an announcement of results, not an announcement *about* a report being published (RPA). Q2 2021
2021-07-15 English
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
Earnings Release Classification · 92% confidence The document is a press release dated July 14, 2021, reporting 'topline results' from clinical studies (Phase 1b and Phase 2a) for a drug candidate (GLPG3970) in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA). It details safety, tolerability, and early clinical effects (PASI scores, Mayo score, DAS28). This content structure—announcing specific clinical trial outcomes and their implications for the drug pipeline—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it focuses purely on the results of clinical trials and not the overall financial performance for a period (which would suggest an IR or 10-K), and it is a formal announcement of results, it fits best under the Earnings Release (ER) category, which often includes key clinical milestones for biotech/pharma companies, or potentially an Investor Presentation (IP) if it were structured as slides, but the format here is a news release. Given the options, 'ER' (Earnings Release) is the closest fit for a formal announcement of period-specific clinical trial results, even if not strictly quarterly financials. However, since it is a detailed report on clinical trial data, it could also be considered an Investor Presentation (IP) if the intent is to present data to investors. Given the context of reporting 'topline results' and discussing the future development of the 'Toledo portfolio,' it functions as a key update for investors. Comparing ER (initial announcement of key highlights) vs IP (detailed presentation): This document provides substantial detail on the results, which leans slightly towards an Investor Presentation (IP) or a very detailed ER. Since it is a press release announcing specific clinical data points, and not a general financial summary, 'IP' (Investor Presentation) is a strong candidate, as these releases often serve as the textual basis for investor presentations. However, 'ER' is often used for the initial release of any significant period-based data (clinical or financial). Given the focus on clinical trial outcomes, 'IP' is often used for detailed data dissemination. Let's re-evaluate based on the definitions. It is not a formal financial report (10-K, IR). It is a release of specific data. If it were a presentation deck, it would be IP. As a press release detailing results, it functions as an ER. I will classify it as an ER as it is the initial public announcement of these results, which often precedes a formal presentation. Q2 2021
2021-07-15 English
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
Earnings Release Classification · 99% confidence The document is a press release dated July 14, 2021, reporting 'positieve topline resultaten' (positive topline results) from a Phase 1b clinical study for a drug candidate (GLPG3667) in psoriasis patients. It details safety, tolerability, and efficacy signals (PASI 50 response rates) and announces plans to start a Phase 2b study. This format—a concise announcement of key clinical trial results, often including quotes from management and future development plans—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it is not a full quarterly/interim report (IR) or a formal regulatory filing like a 10-K, and it focuses purely on announcing results rather than soliciting votes (DEF 14A) or reporting insider trades (DIRS), the most appropriate classification is Earnings Release (ER), as clinical trial updates often accompany or substitute for traditional earnings announcements in biotech/pharma, or it falls under the general announcement category. Given the content is a direct announcement of study results and future plans, ER is the best fit among the specific options, although RNS (Regulatory Filings) is a possibility if ER is strictly reserved for financial earnings. However, ER often covers key operational results like this. Since it is a detailed announcement of results, not just a notice that a report is attached (RPA), ER is chosen. Q3 2021
2021-07-15 English
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
Regulatory Filings Classification · 98% confidence The document is a press release dated July 14, 2021, reporting 'positive topline results' from a Phase 1b clinical study for a drug candidate (GLPG3667) in psoriasis patients. It details efficacy signals (PASI 50 response rates) and safety/tolerability findings. This structure—announcing key clinical trial results and future development plans (Phase 2b initiation)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it is a focused announcement of period results (clinical trial outcome) rather than a comprehensive annual or quarterly financial report (10-K or IR), the most appropriate classification is Earnings Release (ER), as these often include operational highlights alongside any financial context, or sometimes, as a general announcement of significant news, it could fall under RNS. However, given the focus on reporting specific study results and the structure typical of a company communicating key performance indicators (even clinical ones) to the market, ER is a strong fit. It is not a full financial report (10-K/IR), a transcript (CT), or a presentation (IP). It is a direct announcement of results, not just an announcement that a report is coming (RPA). I will classify it as an Earnings Release (ER) due to the reporting of key performance metrics/results.
2021-07-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.